Domestic Trademark Acquired for Combination Cancer Immunotherapy 'SynerTri Immunotherapy®'
NQ Score
34/100
N1 Content Completeness
2
AI Summary (NQ-processed)
A medical group providing precision cancer medicine based on genomic information has acquired the domestic trademark for its combination cancer immunotherapy, 'SynerTri Immunotherapy®'. This move strengthens the branding and intellectual property protection of their personalized treatment strategy.